Ventricular Tachycardia Ablation Outcomes in Patients Without Previous Implantable Cardioverter-Defibrillator Insertion: A Propensity Score-matched Analysis.
Ali Saad Al-Shammari, Ankur Singla, Ameer Awashra, Adishwar Rao, Ahmed Sermed Al Sakini, Ahmed Al-Kaisey, Tarique Ahmed, Sima Rawal, Mohammed Saifuddin, Mohamed Wagdy, Muhammad Bilal Munir, Saif Syed, Keerat Rai Ahuja, Yasar Sattar
{"title":"Ventricular Tachycardia Ablation Outcomes in Patients Without Previous Implantable Cardioverter-Defibrillator Insertion: A Propensity Score-matched Analysis.","authors":"Ali Saad Al-Shammari, Ankur Singla, Ameer Awashra, Adishwar Rao, Ahmed Sermed Al Sakini, Ahmed Al-Kaisey, Tarique Ahmed, Sima Rawal, Mohammed Saifuddin, Mohamed Wagdy, Muhammad Bilal Munir, Saif Syed, Keerat Rai Ahuja, Yasar Sattar","doi":"10.19102/icrm.2026.17033","DOIUrl":null,"url":null,"abstract":"<p><p>Ventricular tachycardia (VT) is a fatal arrhythmia, often managed with implantable cardioverter-defibrillators (ICDs). Many patients, however, present without an ICD. The role of catheter ablation in this high-risk group is unclear, particularly for short-term in-hospital outcomes. We assessed associations between ablation and in-hospital outcomes among ICD-naive VT patients using a large national dataset. We conducted a retrospective study using the National Inpatient Sample (2016-2021), identifying adult hospitalizations with VT. Patients with prior ICDs or ICD implantation during the same admission were excluded. The cohort was divided into those who underwent catheter ablation versus those managed without ablation. Multivariable logistic regression and 1:1 propensity score matching (PSM) adjusted for demographic, clinical, and hospital factors. The primary outcome was in-hospital mortality; secondary outcomes included ST-elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACEs) (death, STEMI, or cardiogenic shock), cardiogenic shock, tamponade, mechanical circulatory support (MCS), acute heart failure, and prolonged hospitalization (≥7 days). Of 2,214,424 VT hospitalizations, 32,640 (1.5%) underwent catheter ablation. After PSM (n = 12,668), ablation was associated with significantly lower rates of in-hospital mortality (3.17% vs. 8.98%; <i>P</i> < .001), STEMI (6.82% vs. 18.83%; <i>P</i> < .001), sepsis (3.38% vs. 10.34%; <i>P</i> < .001), and MACEs (15.82% vs. 28.40%; <i>P</i> < .001). However, ablation was associated with higher rates of cardiac tamponade (1.78% vs. 0.43%; <i>P</i> < .001), cardiogenic shock (9.14% vs. 7.12%; <i>P</i> < .001), and MCS use (5.04% vs. 3.71%; <i>P</i> < .001). Rates of acute heart failure and prolonged hospitalization were comparable. In ICD-naive VT patients, catheter ablation was associated with improved in-hospital survival and fewer complications, albeit with higher procedural risks.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"17 3","pages":"6651-6662"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068033/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Innovations in Cardiac Rhythm Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19102/icrm.2026.17033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Ventricular tachycardia (VT) is a fatal arrhythmia, often managed with implantable cardioverter-defibrillators (ICDs). Many patients, however, present without an ICD. The role of catheter ablation in this high-risk group is unclear, particularly for short-term in-hospital outcomes. We assessed associations between ablation and in-hospital outcomes among ICD-naive VT patients using a large national dataset. We conducted a retrospective study using the National Inpatient Sample (2016-2021), identifying adult hospitalizations with VT. Patients with prior ICDs or ICD implantation during the same admission were excluded. The cohort was divided into those who underwent catheter ablation versus those managed without ablation. Multivariable logistic regression and 1:1 propensity score matching (PSM) adjusted for demographic, clinical, and hospital factors. The primary outcome was in-hospital mortality; secondary outcomes included ST-elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACEs) (death, STEMI, or cardiogenic shock), cardiogenic shock, tamponade, mechanical circulatory support (MCS), acute heart failure, and prolonged hospitalization (≥7 days). Of 2,214,424 VT hospitalizations, 32,640 (1.5%) underwent catheter ablation. After PSM (n = 12,668), ablation was associated with significantly lower rates of in-hospital mortality (3.17% vs. 8.98%; P < .001), STEMI (6.82% vs. 18.83%; P < .001), sepsis (3.38% vs. 10.34%; P < .001), and MACEs (15.82% vs. 28.40%; P < .001). However, ablation was associated with higher rates of cardiac tamponade (1.78% vs. 0.43%; P < .001), cardiogenic shock (9.14% vs. 7.12%; P < .001), and MCS use (5.04% vs. 3.71%; P < .001). Rates of acute heart failure and prolonged hospitalization were comparable. In ICD-naive VT patients, catheter ablation was associated with improved in-hospital survival and fewer complications, albeit with higher procedural risks.
室性心动过速(VT)是一种致命的心律失常,通常采用植入式心律转复除颤器(ICDs)进行治疗。然而,许多患者没有ICD。导管消融在这一高危人群中的作用尚不清楚,特别是对于短期住院结果。我们使用一个大型的国家数据集评估了icd初发VT患者消融与住院预后之间的关系。我们使用全国住院患者样本(2016-2021)进行了一项回顾性研究,确定了患有室速的成人住院患者。排除了同一入院期间既往有ICD或植入ICD的患者。该队列被分为导管消融组和未消融组。多变量logistic回归和1:1倾向评分匹配(PSM)调整了人口统计学、临床和医院因素。主要结局是住院死亡率;次要结局包括st段抬高型心肌梗死(STEMI)、败血症、主要心脏不良事件(mace)(死亡、STEMI或心源性休克)、心源性休克、心包填塞、机械循环支持(MCS)、急性心力衰竭和住院时间延长(≥7天)。在2214424例VT住院患者中,32640例(1.5%)接受了导管消融。PSM (n = 12,668)后,消融与住院死亡率(3.17% vs. 8.98%, P < 0.001)、STEMI (6.82% vs. 18.83%, P < 0.001)、败血症(3.38% vs. 10.34%, P < 0.001)和mace (15.82% vs. 28.40%, P < 0.001)显著降低相关。然而,消融与较高的心脏填塞率(1.78%比0.43%,P < 0.001)、心源性休克(9.14%比7.12%,P < 0.001)和MCS使用(5.04%比3.71%,P < 0.001)相关。急性心力衰竭和长期住院的比率是相当的。在未接受icd治疗的室性心动过速患者中,导管消融可提高住院生存率,减少并发症,但手术风险较高。